ARIA has received different ratings from analysts, according to FactSet. Leerink Swann restated a "positive" rating on shares of ARIAD Pharmaceuticals in a report on Tuesday, November 29th.
On technical side, moving averages may help to distinguish direction of tendencies, and they might also be used to set levels of sustenance and resistance. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company. Barclays PLC's price objective indicates a potential upside of 1.07% from the company's previous close. You can see the complete list of today's Zacks #1 Rank stocks here. The company has a market cap of $2.60B. ARIAD Pharmaceuticals has a 52-week low of $4.37 and a 52-week high of $14.42. (NASDAQ:ARIA)'s stock about -0.40% from the 50-day high and 174.80% away from the 50-day low.
Retail Bank Of America De last reported 120,578 shares in the company. Average recommendation stands as Overweight with consensus analysis of 11 Analysts. The firm owned 128,964 shares of the pharmaceutical company's stock after selling 1,732 shares during the period. ARIAD Pharmaceuticals's revenue was up 58.3% on a year-over-year basis.
The Company has the right to buy down 0.5% percent of the NSR on the claims for US$500,000. "We have tremendous respect for Takeda, and I believe our shared commitment to innovation and research-driven cultures will provide for a smooth transition", acknowledged Ariad Pharmaceuticals Inc President and CEO Paris Panayiotopoulos.
Given the scarcity of commercial-stage oncology assets and significant potential synergies, other Ariad bidders could emerge, SunTrust Robinson analysts said. (NASDAQ:ARIA) on Wednesday, October 5 with "Buy" rating. If you are accessing this article on another website, it was copied illegally and reposted in violation of USA and global copyright & trademark laws.
Investors interested in trading ARIA stock at the current market price of $13.74/share should know the company will next release quarterly results for the December 2017 quarter. The company initiated a $725 million effort to streamline R&D this summer, and a few months later locked down a deal worth up to $790 million with Crescendo Biologics for access to the United Kingdom company's drug conjugate platform. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The firm now has a $24.00 price objective on the pharmaceutical company's stock. Meant to treat a form of non-small cell cancer, the companies said the therapy could have annual peak sales of more than $1 billion. Finally, Family Management Corp increased its position in shares of ARIAD Pharmaceuticals by 0.7% in the second quarter.
ARIAD Pharmaceuticals, Inc. (ARIAD), incorporated on April 12, 1991, is an oncology company. While ARIAD's stock price was collapsing and many shareholders were abandoning the company, Sarissa Capital saw a company with important drugs and innovation and stepped in to become one of ARIAD's leading shareholders.